Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective

Area of Science:

• Oncology
• Urology
• Medical Diagnostics

Background:

• Prostate-specific antigen (PSA) screening has led to earlier prostate cancer diagnoses.
• Early diagnosis increases the number of patients eligible for curative treatments.
• Current standard treatments have limitations, as some patients develop progressive disease despite adequate local therapy.

Purpose of the Study:

• To review current data on neoadjuvant systemic therapy for early-stage prostate cancer.
• To discuss the role of neoadjuvant hormonal and chemotherapy in maximizing cure rates.
• To identify appropriate candidates for neoadjuvant therapy in prostate cancer management.

Main Methods:

• Review of existing clinical data and studies on neoadjuvant therapy in prostate cancer.
• Analysis of outcomes for patients receiving neoadjuvant hormonal therapy.
• Analysis of outcomes for patients receiving neoadjuvant chemotherapy.

Main Results:

• Neoadjuvant therapy is an area of ongoing research for improving prostate cancer cure rates.
• Data on the efficacy of both hormonal and chemotherapy as neoadjuvant treatments are being evaluated.
• Patient selection criteria for neoadjuvant therapy are crucial for optimizing outcomes.

Conclusions:

• Neoadjuvant systemic therapy is a potential strategy to enhance curative treatment effectiveness in early-stage prostate cancer.
• Further research is needed to refine patient selection and optimize neoadjuvant treatment protocols.
• Understanding the limitations of current therapies highlights the importance of exploring novel approaches like neoadjuvant treatment.